These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11399981

  • 1. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
    Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA.
    AIDS; 2001 May 25; 15(8):991-8. PubMed ID: 11399981
    [Abstract] [Full Text] [Related]

  • 2. Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
    Merry C.
    AIDS; 2001 May 25; 15(8):1057-8. PubMed ID: 11399989
    [No Abstract] [Full Text] [Related]

  • 3. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr 25; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb 25; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 6. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
    Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW.
    Br J Clin Pharmacol; 2000 Aug 25; 50(2):108-15. PubMed ID: 10930962
    [Abstract] [Full Text] [Related]

  • 7. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
    Hirani VN, Raucy JL, Lasker JM.
    Drug Metab Dispos; 2004 Dec 25; 32(12):1462-7. PubMed ID: 15448116
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, Roda R, Sacchelli L, Gatti F, Delle Foglie P, Nardini G, Fabris P, Mori F, Castelli P, Testa L.
    Antimicrob Agents Chemother; 2005 Feb 25; 49(2):643-9. PubMed ID: 15673746
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM.
    Br J Clin Pharmacol; 2007 Nov 25; 64(5):634-44. PubMed ID: 17892516
    [Abstract] [Full Text] [Related]

  • 10. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS study group.
    Br J Clin Pharmacol; 2005 Oct 25; 60(4):390-403. PubMed ID: 16187971
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun 25; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 15. The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.
    Jensen-Fangel S, Justesen US, Black FT, Pedersen C, Obel N.
    HIV Med; 2003 Jan 25; 4(1):48-52. PubMed ID: 12534959
    [Abstract] [Full Text] [Related]

  • 16. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M, Wiehler H, Ross B, Möcklinghoff C, Hill A, Becker M, Kurowski M.
    Antivir Ther; 2005 Jan 25; 10(2):349-55. PubMed ID: 15865230
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.
    Pediatr Infect Dis J; 2006 Jun 25; 25(6):538-43. PubMed ID: 16732153
    [Abstract] [Full Text] [Related]

  • 18. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
    Chappuy H, Tréluyer JM, Rey E, Dimet J, Fouché M, Firtion G, Pons G, Mandelbrot L.
    Am J Obstet Gynecol; 2004 Aug 25; 191(2):558-62. PubMed ID: 15343237
    [Abstract] [Full Text] [Related]

  • 19. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
    Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM.
    Ann Pharmacother; 2003 Apr 25; 37(4):521-5. PubMed ID: 12659608
    [Abstract] [Full Text] [Related]

  • 20. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.
    Kattel K, Evande R, Tan C, Mondal G, Grem JL, Mahato RI.
    Br J Clin Pharmacol; 2015 Aug 25; 80(2):267-75. PubMed ID: 25752914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.